



FOR IMMEDIATE RELEASE
April 25, 2011

CONTACT: Lynnor Stevenson, Ph.D., CEO
(503) 688-1941 or Stevenson@designmedix.com

**WORLD MALARIA DAY SEMINAR HIGHLIGHTS NON-PROFITS WITH
MISSIONS THAT TARGET MALARIA**
DesignMedix adds new malaria projects

Portland, Ore., (April 25, 2011) — Monday, April 25 is World Malaria Day, an occasion instituted by the World Health Assembly to raise awareness about the deadly, mosquito-borne disease. Portland State University, Klarquist Sparkman LLP and DesignMedix, Inc. are sponsoring a seminar to highlight efforts to cure and prevent this challenging disease, which infects more than 250 million people per year and kills almost one million.

The seminar will include a talk entitled, “From Bench to Bedside and Back: Translating Global Health Product Needs into Opportunities for Innovation” by Elizabeth Ponder of BioVentures for Global Health (BVGH). BVGH is an independent, non-profit organization whose mission is to save lives by accelerating the development of novel, biotechnology-based drugs, vaccines, and diagnostics that address the unmet medical needs of the developing world. Dr. Ponder has a broad background and interest in infectious diseases and extensive experience in the field of parasitology. At BVGH, Dr. Ponder combines her scientific training and field experience to identify needs, challenges, and opportunities to apply innovation from the biopharmaceutical industry to new products for neglected diseases.

A second presentation entitled, “Technology Solutions for Global Health: Advancing Vaccine Technologies and the Role of Public-Private Partnerships” will be given by Ray Cummings, Senior Commercialization Officer in the Technology Solutions Global Program at PATH, an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. Mr. Cummings role is to establish and manage partnerships to develop improved vaccine and diagnostic products for the developing world. He also manages PATH’s project to develop more stable pandemic influenza vaccines.

DesignMedix Inc. is a Portland-based early stage drug developer that focuses on malaria and other infectious diseases. The company received an orphan drug designation for its first malaria drug, DM1157. The company announced two additional new programs for novel drugs to attack the disease, programs that target prevention of the disease as well as cure. Recent work at PSU has demonstrated that two new series of drugs have important properties. The PROLIVAC series of not only prevent infection by malaria, they also act on the liver stage infections which are “hidden” from most drugs. The SYNAC series are synergistic with other drugs, meaning that when they are combined, the effect is greater than just additive.

All of DesignMedix' drugs overcome drug resistance, which has become a major worldwide concern. The drugs are being developed in partnership with Dr. David Peyton's and Dr. Jane Kelly's laboratories in the Chemistry Department at Portland State University (PSU).

About DesignMedix Inc.

DesignMedix was founded in 2006 to develop drugs to overcome drug resistance with an initial focus on curing malaria. The company's oral drugs target malaria, which kills over a million people per year and affects up to 500 million people. DesignMedix is developing three series of novel, safe and effective drugs that are in preclinical studies and have the potential for low-cost production. For more information please visit <http://www.designmedix.com>

About Portland State University (PSU) Located in Portland, Oregon, PSU has about 30,000 undergraduate and graduate students. PSU's motto is "Let Knowledge Serve the City," and we provide every student with opportunities to work with businesses, schools and organizations on real-world projects. Our downtown campus exhibits PSU's commitment to sustainability with green buildings, while sustainability is incorporated into much of the curriculum.

About Malaria and World Malaria Day

According to UNICEF, a child dies of malaria **every 30 seconds** in Africa. Nearly **one million children** under five years old in sub-Saharan Africa **die each year** from the mosquito-borne disease. Approximately half of the world's population is at risk of malaria, particularly those living in lower-income countries. It infects more than 250 million people per year and kills up to 1 million. The burden of malaria is heaviest in sub-Saharan Africa but the disease also afflicts Asia, Latin America, the Middle East and even parts of Europe. World Malaria Day was instituted by the World Health Assembly at its 60th session in May 2007 as a day for recognizing the global effort to provide effective control of malaria.

###